Baird is keeping their Neutral rating on Regeneron Pharma (NASDAQ: REGN) as the company shows an impressive VEGF Trap-Eye in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE